Lenox Wealth Management’s Alnylam Pharmaceuticals ALNY Stock Holding History

Lenox Wealth Management’s Portfolio ALNY Stock Details ALNY Fund Activity

Bought

Maintained

Sold

Quarter	Market Value	Status	Shares	Change in Stake	Trade Value	Portfolio Weight	Portfolio Position
2020 Q2	$49K	Buy	+336	New	+$45.3K	0.02%	254

Other funds holding ALNY

Fidelity Investments Boston, Massachusetts $1.9T AUM 41.92% 1-Year Est. Return

Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return

Wellington Management Group Boston, Massachusetts $535B AUM 26.23% 1-Year Est. Return

BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return

Baillie Gifford & Co Edinburgh, United Kingdom $97.9B AUM 20.73% 1-Year Est. Return

T. Rowe Price Associates Baltimore, Maryland $865B AUM 30.76% 1-Year Est. Return

Dodge & Cox San Francisco, California $182B AUM 14.68% 1-Year Est. Return

State Street Boston, Massachusetts $2.9T AUM 29.55% 1-Year Est. Return

JP Morgan Chase New York $1.56T AUM 27.86% 1-Year Est. Return

RTW Investments New York $10B AUM 135.35% 1-Year Est. Return

Lenox Wealth Management's ALNY Position: Q2 2020 in Review

Lenox Wealth Management opened a new position in Alnylam Pharmaceuticals (ALNY) in Q2 2020: 336 shares worth $49K. The stake represents 0.02% of the portfolio and ranks #254 among its holdings.

374 funds tracked by Wall St. Rank hold ALNY as of Q2 2020.

Lenox Wealth Management held 336 shares of Alnylam Pharmaceuticals worth $49K as of Q2 2020.
Alnylam Pharmaceuticals was a new Lenox Wealth Management position in Q2 2020.
Alnylam Pharmaceuticals made up 0.02% of Lenox Wealth Management's portfolio in Q2 2020, its #254 holding.
374 funds tracked by Wall St. Rank held Alnylam Pharmaceuticals as of Q2 2020.

Based on Lenox Wealth Management's 13F filing for Q2 2020, filed 28 Jul 2020.